# Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients

> **NCT04269369** · PHASE4 · UNKNOWN · sponsor: **Jessa Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Colon Cancer
- Stomach Tumor
- Anal Tumor
- Pancreas Cancer
- Esophageal Cancer

## Interventions

- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT04269369
- **Lead sponsor:** Jessa Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-18
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269369, "Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04269369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*